{"id":35607,"date":"2013-04-22T12:42:59","date_gmt":"2013-04-22T16:42:59","guid":{"rendered":"http:\/\/1boringoldman.com\/?p=35607"},"modified":"2013-04-22T12:58:24","modified_gmt":"2013-04-22T16:58:24","slug":"retire-the-number","status":"publish","type":"post","link":"https:\/\/1boringoldman.com\/index.php\/2013\/04\/22\/retire-the-number\/","title":{"rendered":"retire the number&#8230;"},"content":{"rendered":"<br \/>\n<blockquote>\n<div align=\"center\"><a href=\"http:\/\/www.pharmalive.com\/uk-charges-glaxo-with-%E2%80%98market-abuse%E2%80%99-for-pay-to-delay-deals\" target=\"_blank\">UK Charges Glaxo With &lsquo;Market Abuse&rsquo; For Pay-To-Delay Deals<\/a><br \/>  <strong><font color=\"#004400\">Pharmalot<\/font><\/strong><br \/>  by Ed Silverman<br \/>  04\/22\/2013<\/div>\n<div><sup><strong>  <\/p>\n<p align=\"justify\">In  the latest instance in which drugmakers have been accused of  reaching?&#8217;pay to delay&#8217; deals that harm consumers, the UK Office of Fair  Trading late last week charged that GlaxoSmithKline colluded with three  generic drugmakers to forestall the introduction of low-cost versions  of its Seroxat antidepressant, which is known as Paxil in the US.<\/p>\n<p align=\"justify\">The  agreements included &quot;substantial payments&quot; made by Glaxo to Alpharma,  Genericks UK and Norton Healthcare in return for a commitment to delay  plans to market generic versions of the antidepressant. In announcing  its charges, the anti-trust regulator noted that if drugmakers?conspire  to delay the potential emergence of generic competition, the UK&#8217;s  National Health Service may be denied significant cost savings.<\/p>\n<div align=\"justify\">&#8216;The  introduction of generic medicines can lead to strong competition on  price, which can drive savings for the NHS, to the benefit of patients  and, ultimately, taxpayers. It is, therefore, particularly important  that the OFT fully investigates concerns that independent generic entry  may have been delayed in this case,&quot; Ann Pope, Senior Director of  Services, Infrastructure and Public Markets at the OFT, said in a  statement&#8230;<\/div>\n<p><\/strong><\/sup><\/div>\n<\/blockquote>\n<div align=\"justify\"><img loading=\"lazy\" decoding=\"async\" border=\"0\" align=\"right\" width=\"136\" vspace=\"5\" hspace=\"4\" height=\"148\" src=\"http:\/\/1boringoldman.com\/images\/paxil.gif\" \/>In the enduring chronicles of the pharmaceutical industry, SmithKlineFench cum GlaxoSmithKline deserves special mention for corporate criminality with their Paxil [Seroxat] antidepressant at every level from the early approval process to even beyond the end of their patent. Their launch meeting in 1993 moderated by Emory&#8217;s Dr. Charlie Nemeroff and organized by STI&#8217;s Sally Laden paired these two icons with this SKF [GSK] medication for a trip through every black art in the PHARMA compendium. Now we read that it lasted beyond the grave of patent expiration. If this were sports, we would retire the number as a testimonial to their persistence and hubris in slithering between the cracks of regulations and the law. <\/div>\n<p align=\"justify\">Sir William Osler said in antiquity that one could learn all of medicine from the study of one disease &#8211; namely Syphilis. Well one could learn all of PHARMA&#8217;s tricks by studying GSK&#8217;s Paroxetine: ghost writing, data manipulation, suppression of adverse effects, KOL corruption, off-label promotion, indication creep, experimercials, etc., and now patent extension payola. They wrote the book [literally &#8211; <a target=\"_blank\" href=\"http:\/\/1boringoldman.com\/index.php\/2011\/04\/11\/csi-miwatch\/\">Recognition and Treatment of Psychiatric Disorders<\/a>].<\/p>\n<p align=\"justify\">The problem is that it was the worst of drugs, and the worst thing about it was that it had enough efficacy to get it on the market and for people to continue taking it. Very early on, my friend&#8217;s wife took it and found it helpful. After a time, she tried to stop it and discovered that it can have a now well-known malicious withdrawal syndrome in some. It took her forever to discontinue it no matter how slowly she decreased the dose. At the time, I had never prescribed the drug and could find nothing in the literature about withdrawal. As I was on the Emory faculty, I called a colleague still on the full-time faculty who was studying the drug. He suggested that my friend&#8217;s wife was having a return of her depression. That wasn&#8217;t right, and I never prescribed the drug myself. So Paroxetine was particularly good at causing akathisia up front, and had a show-stopping withdrawal profile. Oh yeah, it&#8217;s apparently not so good for the yet unborn either.<\/p>\n<div align=\"justify\">I occasionally still see patients on it. I suggest stopping and some can do that with ease. Most can&#8217;t and have given up even trying after many attempts. One said, &quot;It&#8217;s like my Herpes &#8211; forever&quot;&#8230;<\/div>\n","protected":false},"excerpt":{"rendered":"<p>UK Charges Glaxo With &lsquo;Market Abuse&rsquo; For Pay-To-Delay Deals Pharmalot by Ed Silverman 04\/22\/2013 In the latest instance in which drugmakers have been accused of reaching?&#8217;pay to delay&#8217; deals that harm consumers, the UK Office of Fair Trading late last week charged that GlaxoSmithKline colluded with three generic drugmakers to forestall the introduction of low-cost [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_bbp_topic_count":0,"_bbp_reply_count":0,"_bbp_total_topic_count":0,"_bbp_total_reply_count":0,"_bbp_voice_count":0,"_bbp_anonymous_reply_count":0,"_bbp_forum_subforum_count":0,"footnotes":""},"categories":[2],"tags":[],"class_list":["post-35607","post","type-post","status-publish","format-standard","hentry","category-politics"],"_links":{"self":[{"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/posts\/35607","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/comments?post=35607"}],"version-history":[{"count":8,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/posts\/35607\/revisions"}],"predecessor-version":[{"id":42366,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/posts\/35607\/revisions\/42366"}],"wp:attachment":[{"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/media?parent=35607"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/categories?post=35607"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/tags?post=35607"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}